1. Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice.
Invest Ophthalmol Vis Sci 2004;45:3796-3805.
2. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy.
Diabetes 2002;51:3107-3112.
3. Inatani M, Tanihara H, Honjo M, et al. Expression of proteoglycan decorin in neural retina.
Invest Ophthalmol Vis Sci 1999;40:1783-1791.
4. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.
J Exp Med 2003;198:483-489.
5. Downie LE, Pianta MJ, Vingrys AJ, et al. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity.
J Comp Neurol 2007;504:404-417.
6. Kim YH, Chung IY, Choi MY, et al. Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia.
Neurobiol Dis 2007;26:569-576.
7. Dawson VL, Dawson TM. Nitric oxide neurotoxicity.
J Chem Neuroanat 1996;10:179-190.
8. Dawson VL, Dawson TM, London ED, et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Proc Natl Acad Sci U S A 1991;88:6368-6371.
9. Kaur C, Sivakumar V, Foulds WS, et al. Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia.
Invest Ophthalmol Vis Sci 2009;50:5364-5374.
10. Kaur C, Sivakumar V, Foulds WS. Early response of neurons and glial cells to hypoxia in the retina.
Invest Ophthalmol Vis Sci 2006;47:1126-1141.
11. Almeida A, Heales SJ, Bolanos JP, Medina JM. Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion.
Brain Res 1998;790:209-216.
12. Osborne NN, Casson RJ, Wood JP, et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies.
Prog Retin Eye Res 2004;23:91-147.
13. Chemtob S, Hardy P, Abran D, et al. Peroxide-cyclooxygenase interactions in postasphyxial changes in retinal and choroidal hemodynamics.
J Appl Physiol 1995;78:2039-2046.
14. Hardy P, Dumont I, Bhattacharya M, et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy.
Cardiovasc Res 2000;47:489-509.
15. Rey-Funes M, Ibarra ME, Dorfman VB, et al. Hypothermia prevents nitric oxide system changes in retina induced by severe perinatal asphyxia.
J Neurosci Res 2011;89:729-743.
16. Lee EJ, Kim KY, Gu TH, et al. Neuronal nitric oxide synthase is expressed in the axotomized ganglion cells of the rat retina.
Brain Res 2003;986:174-180.
17. Abraham IM, Harkany T, Horvath KM, Luiten PG. Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection?
J Neuroendocrinol 2001;13:749-760.
18. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
Prog Retin Eye Res 2005;24:587-611.
19. Ozdek SC, Aydin B, Gurelik G, et al. Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion.
Int Ophthalmol 2005;26:27-34.
20. Psarra AM, Bochaton-Piallat ML, Gabbiani G, et al. Mitochondrial localization of glucocortocoid receptor in glial (Müller) cells in the salamander retina.
Glia 2003;41:38-49.
21. Hartnett ME, Martiniuk DJ, Saito Y, et al. Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.
Invest Ophthalmol Vis Sci 2006;47:4975-4982.
22. Park YJ, Kim YH, Choi WS, et al. Treatment with triamcinolone acetonide prevents decreased retinal levels of decorin in a rat model of oxygen-induced retinopathy.
Curr Eye Res 2010;35:657-663.
23. Park JW, Park SJ, Park SH, et al. Up-regulated expression of neuronal nitric oxide synthase in experimental diabetic retina.
Neurobiol Dis 2006;21:43-49.
24. Park SH, Kim JH, Kim YH, Park CK. Expression of neuronal nitric oxide synthase in the retina of a rat model of chronic glaucoma.
Vision Res 2007;47:2732-2740.
25. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy.
Invest Ophthalmol Vis Sci 2007;48:5257-5265.
26. Kim WT, Suh ES. Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy.
Korean J Ophthalmol 2010;24:108-118.
27. Jacobson LK, Dutton GN. Periventricular leukomalacia: an important cause of visual and ocular motility dysfunction in children.
Surv Ophthalmol 2000;45:1-13.
28. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger.
Neuron 1992;8:3-11.
29. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology.
Pharmacol Rev 1991;43:109-142.
30. Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials.
J Pediatr 1997;131:844-850.
31. Rotschild T, Nandgaonkar BN, Yu K, Higgins RD. Dexamethasone reduces oxygen induced retinopathy in a mouse model.
Pediatr Res 1999;46:94-100.
32. Wenzel A, Grimm C, Seeliger MW, et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor.
Invest Ophthalmol Vis Sci 2001;42:1653-1659.
33. Gwon JS, Ju WK, Park SJ, et al. The regulatory expression of neuronal nitric oxide synthase in the ischemic rat retina.
Neuroreport 2001;12:3385-3389.
34. Bolanos JP, Almeida A. Roles of nitric oxide in brain hypoxia-ischemia.
Biochim Biophys Acta 1999;1411:415-436.
35. Oh SJ, Kim IB, Lee MY, et al. NOS-like immunoreactive neurons express GABA-like immunoreactivity in rabbit and rat retinae.
Exp Brain Res 1998;120:109-113.